Bernhardt Denise, Sterzing Florian, Adeberg Sebastian, Herfarth Klaus, Katayama Sonja, Foerster Robert, Hoerner-Rieber Juliane, König Laila, Debus Juergen, Rieken Stefan
Department of Radiation Oncology, University Hospital of Heidelberg, Heidelberg, Germany.
Heidelberg Ion-Beam Therapy Center (HIT), Heidelberg, Germany.
Cancer Manag Res. 2018 Mar 26;10:583-588. doi: 10.2147/CMAR.S148395. eCollection 2018.
Treatment of patients with pelvic adenoid cystic carcinoma (ACC) remains a challenge owing to the rarity of the disease, the lack of data, and the relative radioresistance of these tumors.
This case series presents the results of three patients with recurrent or inoperable pelvic ACC treated with intensity-modulated radiotherapy (IMRT) plus carbon ion (C12) boost. Patients received C12 therapy at a dose of 3 Gray equivalents (GyE) (relative biological effectiveness [RBE]) per fraction up to 24 GyE RBE, followed by 50 GyE of photon IMRT in 25 fractions.
IMRT plus C12 ion boost as a definitive or adjuvant treatment for pelvic ACCs seems to be a promising therapeutic option. No unexpected toxicity was detected and the observed toxicity remained consistently low. The initial treatment response is promising and similar to that experienced for head and neck ACCs.
盆腔腺样囊性癌(ACC)患者的治疗仍然是一项挑战,原因在于该疾病罕见、缺乏数据以及这些肿瘤相对具有放射抗性。
本病例系列展示了3例复发性或无法手术的盆腔ACC患者接受调强放疗(IMRT)加碳离子(C12)增敏治疗的结果。患者接受C12治疗,每次剂量为3戈瑞当量(GyE)(相对生物效应[RBE]),总剂量达24 GyE RBE,随后接受25次分割的50 GyE光子IMRT。
IMRT加C12离子增敏作为盆腔ACC的确定性或辅助性治疗似乎是一种有前景的治疗选择。未检测到意外毒性,且观察到的毒性一直较低。初始治疗反应良好,与头颈部ACC的情况相似。